Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Merck
Farmers Insurance
Harvard Business School
Deloitte
Medtronic
Covington
Chinese Patent Office
Citi
US Department of Justice

Generated: October 21, 2017

DrugPatentWatch Database Preview

ADRENACLICK Drug Profile

« Back to Dashboard

Which patents cover Adrenaclick, and when can generic versions of Adrenaclick launch?

Adrenaclick is a drug marketed by Impax Labs Inc and is included in one NDA. There is one patent protecting this drug.

This drug has forty-three patent family members in fifteen countries.

The generic ingredient in ADRENACLICK is epinephrine. There are nineteen drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the epinephrine profile page.

Summary for Tradename: ADRENACLICK

US Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: see list8
Bulk Api Vendors: see list63
Clinical Trials: see list1
Patent Applications: see list8,053
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:ADRENACLICK at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Impax Labs Inc
ADRENACLICK
epinephrine
INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS020800-003Nov 25, 2009BXRXYesYes► Subscribe► SubscribeY ► Subscribe
Impax Labs Inc
ADRENACLICK
epinephrine
INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS020800-004Nov 25, 2009BXRXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: ADRENACLICK

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Impax Labs Inc
ADRENACLICK
epinephrine
INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS020800-003Nov 25, 2009► Subscribe► Subscribe
Impax Labs Inc
ADRENACLICK
epinephrine
INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS020800-004Nov 25, 2009► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: ADRENACLICK

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,187,224Methods performed by medicine injection apparatuses► Subscribe
7,297,136Medicine injection devices and methods► Subscribe
7,927,303Medicine injection devices and methods► Subscribe
7,931,618Apparatuses and methods for injecting medicines to a desired depth► Subscribe
7,621,891Method and apparatus for delivering epinephrine► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: ADRENACLICK

Country Document Number Estimated Expiration
World Intellectual Property Organization (WIPO)2006063015► Subscribe
Australia2005314401► Subscribe
Mexico2007006251► Subscribe
Taiwan200724182► Subscribe
San MarinoP200700024► Subscribe
New Zealand554828► Subscribe
Canada2585707► Subscribe
European Patent Office1904145► Subscribe
Norway20073489► Subscribe
Russian Federation2007124153► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Merck
McKinsey
Chinese Patent Office
Argus Health
US Army
Cipla
Colorcon
Dow
Johnson and Johnson
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot